Janux Therapeutics, Inc.
JANX
$24.28
$1.014.34%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -77.74M | -68.99M | -60.54M | -44.05M | -55.59M |
| Total Depreciation and Amortization | 2.05M | 2.06M | 2.08M | 2.07M | 2.03M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 25.08M | 22.44M | 21.53M | 11.48M | 12.36M |
| Change in Net Operating Assets | 4.62M | 685.00K | -66.00K | -15.98M | -10.30M |
| Cash from Operations | -46.00M | -43.81M | -36.99M | -46.47M | -51.50M |
| Capital Expenditure | -533.00K | -359.00K | -832.00K | -1.28M | -1.76M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -484.14M | -257.66M | -279.99M | -353.67M | -144.43M |
| Cash from Investing | -484.68M | -258.02M | -280.82M | -354.95M | -146.19M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 391.97M | 713.24M | 327.42M | 382.38M | 380.14M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -347.00K | -- | -- | -- | -- |
| Cash from Financing | 391.62M | 713.24M | 327.42M | 382.38M | 380.14M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -139.06M | 411.40M | 9.60M | -19.04M | 182.45M |